Compared side by side

Retatrutide vs mazdutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both add the glucagon receptor to GLP-1, and the glucagon arm adds energy expenditure (shown so far in mice); retatrutide adds GIP as a third target. Mazdutide, from Innovent and Eli Lilly, was approved in China in 2025 and isn’t FDA-approved; retatrutide isn’t approved yet. In their own trials, a 9 mg dose of mazdutide averaged about 17% weight loss at 60 weeks (GLORY-2), and retatrutide’s top dose about 25–28% at 80 weeks in phase 3.

Side by side

ComparedRetatrutideMazdutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asLY3437943IBI362, LY3305677, Xinermei
What it isThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved.
How it worksTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.Once-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups.
Commonly reportedAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.Strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.
Studied rangeResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.Research range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~6 days (measured in early trials in people)~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)
RouteSubQ injectionSubQ injection
Typical runPhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal painNausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide or mazdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Retatrutide

  • Day 1–28 · 2 mg Triple-agonist is kicking in
  • Day 29–84 · 4 mg Dose-response steepens
  • Day 60+ · 9 mg Watch for dysesthesia at higher doses
  • Day 84+ This is a maintenance medication, not a course
  • Day 85–168 · 8 mg Higher steps: strong satiety
  • Day 169–336 No plateau yet at week 48
  • Day 337–476 Phase 3 territory: the headline numbers

Every card for retatrutide, with its sources

Mazdutide

  • Day 1–28 · 2 mg Appetite first, scale later
  • Day 29–56 · 4 mg A maintenance dose, not just a step
  • Day 57–224 · 4 mg Holding at 4 mg
  • Day 57–224 · 6 mg The top labelled dose
  • Day 225–336 Weeks 32 to 48: still moving, more slowly
  • Day 337+ A maintenance medication, not a course

Every card for mazdutide, with its sources

Questions people ask

How long do retatrutide and mazdutide last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes).

How often are retatrutide and mazdutide taken?

Retatrutide: weekly. Route: SubQ injection. Mazdutide: weekly. Route: SubQ injection.

How are retatrutide and mazdutide dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for mazdutide is 2–6 mg, with a 2 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of retatrutide and mazdutide?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For mazdutide: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux.

Each one in full

Track it in the app

PepVault for iPhone

Taking retatrutide or mazdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo